IP Group PLC (IPO) — Investment Research Note

Executive summary

IP Group is a UK-listed evergreen venture capital investor focused on university spin-outs in healthtech, deeptech and cleantech, with major holdings including Oxford Nanopore, the Pfizer Obesity Royalty Interest (originating from Metsera), Istesso, Hysata and stakes in c.80 private companies. Across 2020-2025 NAV per share moved from ~125p (FY20) through a peak, then to 110.4p at Dec 2025 as public-market weakness in ONT and biotech, plus write-downs in Oxa, First Light Fusion and Pulmocide, offset major wins (Featurespace, Hinge Health IPO, Pfizer/Metsera). The single most important valuation point today is the ~41% discount to a 110.4p NAV — providing a margin of safety, but the discount also reflects a persistent structural feature of listed venture NAVs and Level-3 valuation risk.

Fair value estimate

• Methodology: Discount-to-NAV. This is the industry standard for listed VC/PE vehicles. Peers (HgCapital Trust, Molten Ventures, Oakley Capital, ICG Enterprise) trade at discounts ranging from ~10% (higher-quality with cash-generative underlying) to ~45% (venture-style, biotech-heavy).
• Anchoring NAV: 110.4p at 31 Dec 2025 (audited). Post-year-end, listed portfolio rose modestly (ONT +£23m into H2 2025; Hinge Health fully exited at £16.8m). Adjusting for buybacks and portfolio moves through mid-2026, NAV per share estimated broadly stable near 108-115p.
• Discount range applied: 20-32% (peer-typical for venture-heavy but not distressed portfolios with proven realisation track record, £211m gross cash, £128m of Pfizer royalty embedded value)
• Fair value range: 75p – 92p per share → implied market cap £663m – £813m (vs current £570.7m)
• Absolute upside: +16% to +42% at the mid-point c.+30%

Sector context

• Sector classification confirmed: Financials / Financial Services (listed venture/investment company).
• Profile vs peers: Below-average in NAV-per-share cash generation historically (much of the portfolio is R&D-stage biotech/deeptech which doesn't generate cash). Above-average optionality — the Pfizer obesity licence is a genuinely distinctive royalty asset. Balance sheet more leveraged than pure listed PE peers (£122.8m private placement debt, though offset by cash).
• Listed peers: Molten Ventures (EMV.L — closest peer, similar deeptech/university focus), Augmentum Fintech (AUGM.L — fintech VC), Oakley Capital Investments (OCI.L — European PE, more mature).

Investment thesis (3 bullets)

• Discount to NAV plus embedded Pfizer obesity optionality: Trading at ~41% discount to 110.4p NAV, with £128.2m of Pfizer obesity royalty value (Metsera acquisition by Pfizer for up to $10bn; PF'3944 in Phase 3) representing 13% of NAV alone. Genuine call option on a $150bn+ obesity market with multiple shots on goal (four programmes). 2026-03 annual results
• Capital return discipline + buyback narrowing: £75m buyback completed in 2025 retiring 9% of share capital at ~47.5p; further £30m accumulated for 2026 returns. Board explicit that buybacks continue while discount >20%. 2026-03 annual results
• Realisation track record improving: £68.1m proceeds in 2025 (£183.4m in 2024 including Featurespace sale to Visa). Committed to £250m of exits 2025-2027. Hinge Health NYSE IPO delivered 53x on cost; Monolith sold to CoreWeave. 2026-03 annual results

Key risks (3 bullets)

• Level-3 valuation uncertainty and portfolio concentration: Only 15% of the portfolio is quoted; Pfizer royalty (£128m) and Istesso (£93m) alone are 23% of NAV, both DCF-based with high estimation uncertainty (Istesso lead trial missed primary endpoint in 2024). Sensitivity: +/-5% on clinical trial success rates moves the Pfizer royalty by ±£26m. 2026-03 annual results, Note 28
• Governance friction and covenant technical breach: 34%+ shareholder opposition to remuneration report and buyback resolutions at 2026 AGM; three resolutions (13, 14, 16) failed to pass. Inadvertent covenant breach in year (waiver obtained post period-end) — indicates ongoing frictions with debt holders and shareholders. 2026-06 AGM results; 2026-03 annual results, Note 20
• AI wave largely bypasses IP Group: No material direct AI receiver exposure. Some portfolio names (Lumai optical AI, Intrinsic memory, Accelercomm 5G) are picks-and-shovels but small individually; Monolith AI already sold at modest £3.4m realisation. 2026-03 annual results

Operating leverage

IP Group is not a classical operating-leverage business. Net overheads of £15.9m in 2025 (1.6% of NAV) are the fixed cost base; portfolio returns flow more or less 1:1 to NAV growth. Where operating leverage does exist is in the LICENCE/royalty stream — the Pfizer obesity royalty and Carrick Therapeutics licence generate cash with near-zero incremental cost, so if additional Pfizer programmes reach commercialisation, the £99.1m intangible asset could re-rate materially against essentially the same £15.9m cost base. Similarly, the Parkwalk fund management business is highly scalable (£29m third-party raised in 2025 at ~1.5% AUM fees). But at group level, a 10-20% "revenue" (portfolio gains) surprise would translate to a similar percentage NAV movement — not the 2-3x amplification the investor is seeking. 2026-03 annual results, Financial Review

Value-trap signals

• Persistent NAV discount: Discount has been elevated (30-50%+) for multiple years despite buybacks — the market questions the durability of private valuations.
• AGM shareholder revolt: >20% opposition on multiple resolutions is a governance red flag.
• NAV decline trajectory 2022-2024: NAV per share fell from 167p (2021) → 133p (2022) → 115p (2023) → 98p (2024) before recovering to 110p (2025), reflecting the biotech/growth de-rating. Recovery is real but shows the model's exposure to cycle.
• Covenant technical breach in 2025: Indicates operational weakness in treasury oversight.

Earnings vs expectations

As an investment company, IP Group reports NAV performance rather than earnings guidance. Return on NAV pattern 2020-2025: +7% (2025), -17% (2024), -13% (2023), -20% (2022), +34% (2021), +17% (2020). Cash realisation guidance of >£250m for 2025-2027 was set in 2024; 2025 delivered £68.1m (on track but heavily back-end weighted). ONT revenue guidance has been consistently met by that portfolio company. Overall pattern: highly volatile, benchmark-agnostic, with several MISSES on NAV growth targets across 2022-2024 offset by realisation successes. Not a "beat" story.

Conviction

Conviction: 3 (moderate).

• Anchors: (1) Discount to NAV framework is the appropriate methodology and mechanically anchored; (2) NAV itself is audited and portfolio disclosures are extensive; (3) Realisations provide a real-world calibration point.
• Limits: (1) 85% of portfolio is Level-3 (unquoted) with wide reasonable-value ranges — Istesso alone has a valuation range of £66-144m; Pfizer royalty is highly sensitive to clinical trial success; (2) Discount could remain wide indefinitely — this is a rating, not fundamental, call. A 25% or 40% assumed discount produces meaningfully different fair values.

Driver scoring rationale

• AI beneficiary: 28 — Small portfolio exposure to picks-and-shovels (Lumai optical AI, Intrinsic memory); AI value flows to portfolio company acquirers not IPO
• Operating leverage: 35 — Fixed £15.9m cost base is small relative to NAV; some leverage in royalty stream but overall NAV moves ~1:1 with portfolio returns
• Earnings surprise trend: 40 — Volatile NAV performance, missed several years, hit target 2025
• Cyclicality: 60 — Venture is inherently pro-cyclical to biotech/growth risk appetite
• Moat: 45 — University partnerships (Oxford, Cambridge, Imperial) provide differentiated deal flow but not a durable moat
• Leverage: 45 — £120m private placement + technical covenant issues; net cash still positive
• Earnings quality: 45 — Fair-value accounting means "earnings" are largely mark-to-model on Level-3 assets
• Management quality: 55 — Track record of returns is decent (Featurespace 5.9x, Hinge 53x), governance friction with AGM
• Growth momentum: 50 — Returned to NAV growth in 2025 after three down years

Overall score: 340 — Fair-price discount investment with a genuine embedded call option on the Pfizer obesity royalty, but this stock does not match the investor's core criteria of direct AI exposure, high operating leverage or ambitious multi-bagger AI upside. It's a value/special situations name, not a growth/AI-receiver name.